1.2 Secondary 
1.3 Exploratory 
2.2 AMG 162 Background 
2.2.1 Preclinical Studies 
2.2.1.1 Pharmacokinetic Studies 
2.2.1.2 Toxicology Studies 
2.2.2 Safety Profile 
2.2.3 Clinical Efficacy 
2.3 Rationale 
2.4 Clinical Hypothesis 
3.2 Number of Centers 
3.3 Number of Subjects 
3.4 Estimated Study Duration 
3.4.1 Safety Follow up phase 
4. SUBJECT ELIGIBILITY 
4.1 Inclusion Criteria 
4.1.1 Histologically or cytologically confirmed adenocarcinoma of the breast 
4.1.4 Female (cid:116) 18 years of age 
4.1.5 ECOG Performance status 0 and 1 
4.2 Exclusion Criteria 
4.2.2 Evidence of distant metastases 
4.2.3 Prior history of non traumatic fracture or vertebral fracture after the age of 25 
4.2.10 Recurrence of the primary malignancy 
4.2.12 Evidence of any of the following conditions per subject self report or chart review: 
4.2.13 Inadequate organ function as defined by the following criteria: 
4.2.14 25 hydroxy Vitamin D 12 ng/mL 
4.2.16 Currently enrolled in or has not yet completed at least 4 weeks washout since 
4.2.17 Known sensitivity to mammalian derived products 
4.2.19 Self reported drug or alcohol abuse within the previous 24 weeks before study 
5. SUBJECT ENROLLMENT 
5.1 Subject Identification Number Assignment 
5.2 Randomization 
6.3 Concomitant Therapy 
6.4 Proscribed Therapy During the Treatment Period 
7. STUDY PROCEDURES 
7.1 Medical History 
7.2 Medication History 
7.3 Physical Examination 
7.4 Vital Signs 
7.5 Blood and Laboratory Assessments 
7.5.1 Biomarker Development 
7.6 Calcium and Vitamin D Supplementation 
7.7 Dual X ray Absorptiometry (DXA) Assessment 
7.7.1 Screening DXA 
7.7.2 On Study DXA 
7.9 Non vertebral Fracture Recording 
7.10 Bone and Cartilage Marker 
7.11 Concomitant Therapy 
7.12 Adverse Events 
7.13 Information Collected During Safety Follow Up Phase
8.2 Removal From Study Medication 
8.3 Replacement of Subjects 
9.1.1 Adverse Events 
9.1.2 Serious Adverse Events 
9.2 Reporting Procedures for All Adverse Events 
9.3 Serious Adverse Event Reporting Procedures 
10.2.1 Endpoints 
10.2.2 Covariates 
10.2.3 Stratification 
10.2.4 Subsets 
10.3 Sample Size Considerations 
10.4 External Data Monitoring Committee 
10.5 Interim Analysis and Early Stopping Guidelines 
10.6 Planned Methods of Analysis 
10.6.1 General Approach/Considerations 
10.6.2 Analysis of Key Study Endpoints 
10.6.2.1 Efficacy Endpoints 
10.6.2.2 Safety Endpoints 
10.6.2.3 Exploratory Analyses 
11.2 Access to Blinded Investigational Product Assignment 
12.2 Independent Ethics Committee/Institutional Review Board 
12.3 Prestudy Documentation Requirements 
12.4 Subject Confidentiality 
12.5 Investigator Signatory Obligations 
13.2 Study Documentation and Storage 
13.3 Study Monitoring and Data Collection 
13.4 Language 
13.5 Publication Policy 
13.6 Compensation 
